Navigation Links
Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
Date:9/15/2008

DENVER, Sept. 15 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, September 25, 2008, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2008, and the status of the Company's product development and marketing activities.

Corgenix invites all those interested in hearing management's discussion of the annual results to join the call by dialing:

US attendees: (800) 894-5910

International attendees: +1 785 424 1052

Conference code is: CORGENIX

A question-and-answer session will follow the presentation by Corgenix management.

A replay will be available for 30 days following the call by dialing (800) 374-0934 for US participants and +1 402 220 0680 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin non-responsiveness. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Corgenix Expands Scientific Advisory Board
2. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
3. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
4. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
5. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
6. Corgenix Signs Technology Licensing Agreement With Japanese Government
7. MannKind to Present at the UBS Global Life Sciences Conference
8. Insmed to Present at Biosimilars 2008 Conference
9. Modigene to Present at the UBS Global Life Sciences Conference
10. Vical to Present at UBS Global Life Sciences Conference
11. Stryker to Host Conference Call on October 16, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):